scholarly journals Lenalidomide Maintenance for High-Risk Multiple Myeloma after Allogeneic Hematopoietic Cell Transplantation

2014 ◽  
Vol 20 (8) ◽  
pp. 1183-1189 ◽  
Author(s):  
Melissa Alsina ◽  
Pamela S. Becker ◽  
Xiaobo Zhong ◽  
Alexia Adams ◽  
Parameswaran Hari ◽  
...  
2020 ◽  
Vol 56 (1) ◽  
pp. 202-209 ◽  
Author(s):  
Sherilyn A. Tuazon ◽  
Brenda M. Sandmaier ◽  
Theodore A. Gooley ◽  
Darrell R. Fisher ◽  
Leona A. Holmberg ◽  
...  

2017 ◽  
Vol 1 (24) ◽  
pp. 2247-2256 ◽  
Author(s):  
Damian J. Green ◽  
David G. Maloney ◽  
Barry E. Storer ◽  
Brenda M. Sandmaier ◽  
Leona A. Holmberg ◽  
...  

Key Points Patients with high-risk multiple myeloma have a median survival of <3 years. Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy improves survival in these patients.


2017 ◽  
Vol 23 (3) ◽  
pp. S266 ◽  
Author(s):  
Patrick A. Hagen ◽  
Tulio E. Rodriguez ◽  
Scott Smith ◽  
Stephanie Tsai ◽  
Zeina Al-Mansour ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document